Thymopentin

Thymopentin

SCHEMBL270731

CC(=O)O.CC(C)[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)O

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Thymopentin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
NPY4R P50391 13/20 0.60
NPY1R P25929 8/20 0.60
NPY2R P49146 6/20 0.60
NPY5R Q15761 5/20 0.60
IL23R Q5VWK5 2/20 0.51
TFPI P10646 1/20 0.51
OPRD1 P41143 1/20 0.50
VIPR2 P41587 2/20 0.49
VIPR1 P32241 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Thymopentin SCHEMBL29512423 0.98 NPY4R (0.62) NPY4RNPY1RNPY2RNPY5RIL23R
SCHEMBL30331711 0.98 NPY4R (0.62) NPY4RNPY1RNPY2RNPY5RIL23R
Thymopentin SCHEMBL989519 0.98 NPY4R (0.62) NPY4RNPY1RNPY2RNPY5RIL23R
Thymopentin SCHEMBL7498758 0.98 NPY4R (0.62) NPY4RNPY1RNPY2RNPY5RIL23R
Thymopentin SCHEMBL44001 0.98 NPY4R (0.62) NPY4RNPY1RNPY2RNPY5RIL23R
Thymopentin SCHEMBL29512388 0.98 NPY4R (0.62) NPY4RNPY1RNPY2RNPY5RIL23R
Thymopentin SCHEMBL29512397 0.98 NPY4R (0.62) NPY4RNPY1RNPY2RNPY5RIL23R
SCHEMBL29611531 0.96 NPY4R (0.64) NPY4RNPY1RNPY2RNPY5RIL23R
Acetic Acid SCHEMBL6940231 0.95 NPY4R (0.67) NPY4RNPY1RNPY2RNPY5RIL23R
SCHEMBL30918767 0.95 NPY4R (0.57) NPY4RNPY1RNPY2RNPY5RIL23R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10946141-B2 Sterile protective cover comprising a device for opthalmic delivery VIRCHOW BIOTECH PVT. LTD. (IN) 2021-03-16 US disclosed
EP-2505189-B1 Stabilizing alkylglycoside compositions and method thereof AEGIS THERAPEUTICS LLC (US) 2018-08-08 EP disclosed
US-20180140461-A1 STERILE PROTECTIVE COVER COMPRISING A DEVICE FOR OPTHALMIC DELIVERY VIRCHOW BIOTECH PVT. LTD. (IN) 2018-05-24 US disclosed
US-20180092770-A1 STERILE PROTECTIVE COVER COMPRISING A DEVICE FOR OPTHALMIC DELIVERY VIRCHOW BIOTECH INC. 2018-04-05 US disclosed
US-20170258633-A1 NOVEL DEVICE FOR OPHTHALMIC DELIVERY VIRCHOW BIOTECH PVT. LTD. (IN) 2017-09-14 US disclosed
US-20170239335-A1 STABLE INJECTABLE COMPOSITION OF PHARMACEUTICALLY ACTIVE AGENTS AND PROCESS FOR ITS PREPARATION PIRAMAL ENTPR LTD (IN) 2017-08-24 US disclosed
EP-3206706-A1 STABLE INJECTABLE COMPOSITION OF PHARMACEUTICALLY ACTIVE AGENTS AND PROCESS FOR ITS PREPARATION Piramal Enterprises Limited (IN) 2017-08-23 EP disclosed
US-20170216397-A1 STABILIZING ALKYLGLYCOSIDE COMPOSITIONS AND METHODS THEREOF AEGIS THERAPEUTICS, LLC 2017-08-03 US disclosed
EP-2303237-B1 PREPARATION METHOD OF BIODEGRADABLE MICRO-PARTICLES CONTAINING DRUGS UNIV ARKANSAS (US) 2017-03-08 EP disclosed
US-9446134-B2 Stabilizing alkylglycoside compositions and methods thereof AEGIS THERAPEUTICS, LLC (US) 2016-09-20 US disclosed
US-7390788-B2 Pharmaceutically active peptide T composition comprising non-aggregated D-ala1-Peptide T-amide, produced by suspending the D-ala1-Peptide T-amide in 80% trifluoroethanol for 24 hours at 37 C with shaking, removing trifluoroethanol, and suspending the D-ala1-Peptide T-amide in aqueous solution PEPTIDE ACCOUNT LLC 2008-06-24 US disclosed
US-20070298010-A1 Stabilizing alkylglycoside compositions and methods thereof AEGIS THERAPEUTICS LLC (US) 2007-12-27 US disclosed
WO-2007149096-A1 STABILIZING ALKYLGLYCOSIDE COMPOSITIONS AND METHODS THEREOF AEGIS THERAPEUTICS, INC. (US) 2007-12-27 WO disclosed
US-20070111938-A1 Peptide pharmaceutical compositions RAPID PHARMACEUTICALS, LLC (US) 2007-05-17 US disclosed
WO-2007002465-A2 STABILIZING ALKYLGLYCOSIDE COMPOSITIONS AND METHODS THEREOF RAPID PHARMACEUTICALS, LLC (US) 2007-01-04 WO disclosed
EP-0391218-B1 Agent for the atopy prophylaxis BEIERSDORF AG (DE) 1996-03-13 EP disclosed
EP-0324659-B1 Enzymatic process for producing immunomodulating pentapeptides and intermediates for use in the process CARLBIOTECH LTD AS (DK) 1995-08-02 EP disclosed
EP-0391218-A2 Agent for the atopy prophylaxis Beiersdorf Aktiengesellschaft (DE) 1990-10-10 EP disclosed
WO-1989006656-A1 ENZYMATIC PROCESS FOR PRODUCING IMMUNOMODULATING PENTAPEPTIDES AND INTERMEDIATES FOR USE IN THE PROCESS CARLSBERG BIOTECHNOLOGY LTD. A/S (DK) 1989-07-27 WO disclosed
EP-0324659-A2 Enzymatic process for producing immunomodulating pentapeptides and intermediates for use in the process CARLBIOTECH LTD. A/S (DK) 1989-07-19 EP disclosed